The company utilizes its BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its clinical pipeline includes BHT-3021, currently in Phase I/II clinical trial for reducing or eliminating the immune system's attack on the pancreas; BHT-3009, which has completed Phase II trial for multiple sclerosis treatment; and BHT-3034, currently in preclinical studies for myasthenia gravis treatment. Bayhill Therapeutics was founded in 2000 and is headquartered in Palo Alto, California.